Search

Search Constraints

You searched for: Author/Creator Catalano, Lucio

Search Results

2. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in the Prediction of Outcome of Patients With Multiple Myeloma: A Comparative Study. (April 2015)

4. Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients. (9th November 2021)

5. An 1H NMR study of the cytarabine degradation in clinical conditions to avoid drug waste, decrease therapy costs and improve patient compliance in acute leukemia. Issue 1 (January 2020)

6. An NMR Study of the Bortezomib Degradation under Clinical Use Conditions. (14th April 2009)

7. An NMR Study of the Bortezomib Degradation under Clinical Use Conditions. (14th April 2009)

8. Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case‐matched study. Issue 4 (5th February 2014)

9. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. Issue 12 (December 2020)

10. Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials. Issue 5 (6th June 2022)